Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.
about
The cytoskeleton in papillomavirus infectionLessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteinsTarget cell cyclophilins facilitate human papillomavirus type 16 infectionIdentification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implicationsMultiscale simulation of microbe structure and dynamics.Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus.Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines.Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16.Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus.The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies.Principles of polyoma- and papillomavirus uncoating.Human papillomavirus major capsid protein L1 remains associated with the incoming viral genome throughout the entry process.A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragmentCrystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus
P2860
Q26861667-6D200434-67D5-46DB-A336-437C8704FD0BQ27013018-D0797E4D-011A-42D9-9289-03FAEB2A3D21Q28475787-A51ABABC-3863-4442-A083-D1F99449FEBFQ33469751-6ADBD154-CA24-42AA-98D6-5FFBC1F84B9FQ36058098-CBE350A2-D248-4BFC-8B0B-5211F1C143D0Q36099326-16C93839-8010-4084-89E4-3AC709339C41Q36736614-513D0378-61F1-46D3-A71C-9D3CEEFC7D24Q37162220-C10BBFA0-3277-4031-A7F2-0B76539F6E72Q37252724-9BEA13CF-59DB-433F-BEDC-C1266B49ECC3Q37480444-116F2CB8-1877-47E6-BDF3-0E199B908725Q37526148-25C178D5-4AB6-45A3-AC04-257FEE5E2A34Q38045782-96DF8CBE-21B4-4772-A9CA-BD70E5980B85Q38752656-CAA7D2A3-9E12-4E33-BBD6-E240B4358D09Q41606985-DB7FAE96-F34F-421A-AE8B-8BBAB7DB4E34Q41676237-7601B0A3-DECE-4B45-9782-01D8FB3EF1CB
P2860
Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Characterization of neutralizi ...... human papillomavirus type 33.
@ast
Characterization of neutralizi ...... human papillomavirus type 33.
@en
type
label
Characterization of neutralizi ...... human papillomavirus type 33.
@ast
Characterization of neutralizi ...... human papillomavirus type 33.
@en
prefLabel
Characterization of neutralizi ...... human papillomavirus type 33.
@ast
Characterization of neutralizi ...... human papillomavirus type 33.
@en
P2093
P2860
P356
P1433
P1476
Characterization of neutralizi ...... human papillomavirus type 33.
@en
P2093
Hans-Christoph Selinka
Martin Sapp
Rolf E Streeck
Stefanie D Roth
P2860
P356
10.1186/1743-422X-3-83
P577
2006-10-02T00:00:00Z